Summit Therapeutics plans interim PFS analysis for HARMONi-3 squamous cohort in Q2 2026 as clinical pipeline expands
Source: SeekingAlpha
2026-02-24 03:55:40 ET
More on Summit Therapeutics
- Summit Therapeutics Inc. (SMMT) Q4 2025 Earnings Call Transcript
- Summit Therapeutics Inc. 2025 Q4 - Results - Earnings Call Presentation
- Summit Therapeutics: PDUFA Coming, But Is It Good Enough? (Rating Upgrade)
- Summit Therapeutics Q4 2025 Earnings Preview
- Summit spikes as lead asset undergoes FDA review
Read the full article on Seeking Alpha
For further details see:
Summit Therapeutics plans interim PFS analysis for HARMONi-3 squamous cohort in Q2 2026 as clinical pipeline expands
Summit Therapeutics Inc.
NASDAQ: SMMT
SMMT Trading
5.58% G/L:
$16.28 Last:
762,302 Volume:
$15.61 Open:
SMMT Latest News
SMMT Stock Data
$11,408,581,895
112,410,823
0.02%
74
N/A
Biotechnology & Life Sciences
Healthcare
US
Miami
